IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3
IRIDEX CORP
Financials through Q2 FY2026, quarter ended Jul 4, 2026Last filing: 10-Q on Aug 18, 2026
$0.77−0.04 (-5.48%)
Close on Oct 19, 2026
- Market cap
- $13.41M
- P/E (TTM)
- –
- Dividend yield
- –
IRIDEX CORP revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Retina | $6.49M | $5.83M | $8.89M | $6.70M | $8.05M | $6.65M | $7.31M | $6.45M | $7.30M | $6.77M | $7.51M | $7.87M | 51.6% | -19.4% |
| Cyclo G6 | $3.92M | $3.64M | $3.83M | $3.54M | $3.29M | $3.18M | $3.28M | $3.13M | $3.34M | $2.95M | $3.09M | $3.04M | 31.2% | +19.0% |
| Other | $2.16M | $2.33M | $2.00M | $2.25M | $2.23M | $2.07M | $2.11M | $2.00M | $2.00M | $2.03M | $1.86M | $1.94M | 17.2% | -3.1% |
| Service Contract Revenues | $305.00K | $349.00K | – | $400.00K | $654.00K | $334.00K | $999.00K | $1.00M | $600.00K | $328.00K | $334.00K | $400.00K | 2.4% | -53.4% |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $5.13M | $5.87M | $6.58M | $5.59M | $5.76M | $5.28M | $6.31M | $5.46M | $5.60M | $5.32M | $6.40M | $6.14M | 40.8% | -11.0% |
| Europe, Middle East and Africa | $3.45M | $3.34M | $3.84M | $4.03M | $3.65M | $2.86M | $2.66M | $2.80M | $2.67M | $3.70M | $2.30M | $4.20M | 27.5% | -5.5% |
| Asia/Pacific Rim | $3.41M | $2.04M | $3.85M | $2.07M | $3.68M | $3.36M | $3.20M | $2.71M | $3.60M | $2.44M | $3.47M | $2.14M | 27.1% | -7.2% |
| Americas, excluding the U.S. | $575.00K | $550.00K | $449.00K | $797.00K | $483.00K | $392.00K | $532.00K | $607.00K | $769.00K | $298.00K | $285.00K | $377.00K | 4.6% | +19.0% |
| Rest of Americas | – | – | – | – | – | – | – | – | – | – | – | $377.00K | – | – |
| Europe, Middle East and Africa | – | – | – | – | – | – | – | – | – | – | – | $4.20M | – | – |
From the segment and revenue-disaggregation notes of Iridex's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.